Author

Hana Ju

Observed name: Ju, Hana

Institution: Celltrion (South Korea)

Observed institution: Celltrion (South Korea)

ORCID: 0000-0002-9504-9995

Observed ORCID: 0000-0002-9504-9995

OpenAlex ID: A5031357547

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

2022 · Claire Verschraegen, Zoran Andric, et al. · BioDrugs · 13

A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea

2023 · Jae-Cheol Jo, Youngwoo Jeon, et al. · Expert Opinion on Biological Therapy · 3

Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study

2024 · Min Ho Park, Jae Hong Seo, et al. · Expert Opinion on Biological Therapy · 2

Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer

2025 · Zoran Andric, Fedor Moiseenko, et al. · Cancer Treatment and Research Communications

Real-world safety and effectiveness of CT-P6 (biosimilar trastuzumab): A post-marketing surveillance study in Korea.

2023 · Min-Ho Park, Tea Hyun Kim, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 18

H-index: 2

I10-index: 1